BCAX
Bicara Therapeutics Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.44B
P/E Ratio
—
EPS
$-2.52
Beta
—
52W High
$24.25
52W Low
$7.80
50-Day MA
$19.68
200-Day MA
$16.05
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-155.50M |
| Operating Margin | 0.00% |
| Return on Equity | -30.90% |
| Return on Assets | -20.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.37 |
| Price-to-Book | 3.58 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $65.60M |
| Float | $42.30M |
| % Insiders | 10.27% |
| % Institutions | 93.51% |
Historical Volatility
HV 10-Day
33.61%
HV 20-Day
44.95%
HV 30-Day
43.90%
HV 60-Day
50.08%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($30.50 target)
2
Strong Buy8
Buy3
HoldData last updated: 4/29/2026